Effects of Docetaxel Combined with Icotinib on Serum Tumor Markers and Quality of Life of Patients with Advanced Non-Small Cell Lung Cancer

  • Huawei LIN Department of Medicine, Shandong Medical College, Jinan 250002, P.R. China
  • Jing CHANG Department of Medical Oncology, The Third Affiliated Hospital, Shandong First Medical University, Affiliated Hospital of Shan-dong Academy of Medical Sciences, Jinan 250031, P.R. China
  • Jun LI Mail Department of Medical Oncology, The Third Affiliated Hospital, Shandong First Medical University, Affiliated Hospital of Shan-dong Academy of Medical Sciences, Jinan 250031, P.R. China
Keywords:
Docetaxel, Icotinib, Paclitaxel, Carboplatin, Cancer

Abstract

Background: To investigate the effects of docetaxel combined with icotinib on tumor markers in serum and quality of life of patients with advanced non-small cell lung cancer (NSCLC).

Methods: Overall, 121 patients with advanced NSCLC, admitted to the Third Affiliated Hospital of Shandong First Medical University, China from 2017- 2018 were selected as subjects. Among them, 58 patients treated with docetaxel combined with icotinib for chemotherapy were considered as study group, and 63 patients treated with paclitaxel combined with carboplatin as control group. The clinical efficacy, adverse reactions, and ECOG scores of the two groups were observed. CEA, CA125, and SCC (Tumor markers) levels of the two groups before and after treatment were detected by chemiluminescence immunoassay (CLIA).

Results: The leukopenia, oral mucosa ulcer and mild numbness in the control group were significantly higher than those in the study group (P<0.05). After treatment, ECOG scores of both groups decreased (P<0.05), and the ECOG score of the study group was significantly higher than that of the control group (P<0.05). The serum CEA, CA125 and SCC levels of the study group and the control group after treatment decreased significantly compared with that before treatment (P<0.05).

Conclusion: Application of docetaxel combined with icotinib for chemotherapy of patients with advanced NSCLC can effectively reduce the serum levels of CEA, SCC, and the CA125. Docetaxel combined with icotinib can significantly reduce adverse reactions and better improve the quality of life of patients compared with paclitaxel combined with carboplatin, which is worthy of clinical promotion.

References

1. Zhang Y, Hu YP, Ma ZL, et al (2018). Pro-gress of targeted drugs and diagnostic markers for non-small-cell lung cancer in precision medicine. Transl Med J, 007(003): 182-187.
2. Xie Z, Gao X, Cheng K, et al (2017). Corre-lation between the presence of circulating tumor cells and the pathologic type and staging of non-small cell lung cancer dur-ing the early postoperative period. Oncol Lett, 14(5): 5825-5830.
3. Tang N, Zhang Q, Fang S, et al (2017). An-ti-tumor activity of high-dose EGFR ty-rosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xeno-grafts. Oncotarget, 8(6): 9134-9143.
4. DeVita VT Jr, Chu E (2008). A history of cancer chemotherapy. Cancer Res, 68(21): 8643-8653.
5. Hamilton G, Rath B (2018). Pharmacogenet-ics of platinum-based chemotherapy in non-small cell lung cancer: predictive va-lidity of polymorphisms of ERCC1. Ex-pert Opin Drug Metab Toxicol, 14(1): 17-24.
6. Sone K, Oguri T, Ito K, et al (2017). Predic-tive Role of CYFRA21-1 and CEA for Subsequent Docetaxel in Non-small Cell Lung Cancer Patients. Anticancer Res, 37(9): 5125-5131.
7. Gong J, He L, Ma J, et al (2017). The rela-tionship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance. J BUON, 22(2): 454-461.
8. Wee P, Wang Z (2017). Epidermal growth factor receptor cell proliferation signaling pathways. Cancers(Basel), 9(5): E52.
9. Xu J, Liu X, Yang S, et al (2017). Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treat-ment failure: a retrospective study. Onco Targets Ther, 10: 4989-4995.
10. Mohan A, Poulose R, Gupta T, et al (2017). Impact of chemotherapy on symptom profile, oxidant-antioxidant balance and nutritional status in non-small cell Lung Cancer. Lung India, 34(4): 336-340.
11. Oya Y, Yoshida T, Kuroda H, et al (2017). Clinical Efficacy of Alectinib in Patients with ALK-Rearranged Non-small Cell Lung Cancer After Ceritinib Failure. Anti-cancer Res, 37(11): 6477-6480.
12. Takahashi M, Takahashi M, Komine K, et al (2017). The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients: A retro-spective, single institutional study. Plos One, 12(6): e0179694.
13. Gao L, Zhang H, Zhang B, et al (2018). A novel long non-coding RNATCONS_00001798 is downregulat-ed and predicts survival in patients with non-small cell lung cancer. Oncol Lett, 15(4): 6015-6021.
14. Grilli R, Oxman AD, Julian JA (1993). Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol, 11(10): 1866-1872.
15. Li SL, Ma YY, Xiong Y, et al (2018). Role of Serum Tumor Markers in Prognosis of Operable Non-small Cell Lung Cancer Patients. Cancer Research on Prevention & Treatment, 45.
16. Wang X, Ma K, Yang Z, et al (2017). Sys-tematic Correlation Analyses of Circulat-ing Tumor Cells with Clinical Variables and Tumor Markers in Lung Cancer Pa-tients. J Cancer, 8(15): 3099-3104.
17. Zang H, Peng J, Wang W, et al (2017). Roles of microRNAs in the resistance to plati-num based chemotherapy in the non-small cell lung cancer. J Cancer, 8(18): 3856-3861.
18. Zhang Y, Chang, Zhang J (2017). Research Advances in Resistance to Platinum-based Chemotherapy in Lung Cancer. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 39(1): 150-155.
19. Doddapaneni R, Patel K, Chowdhury N, et al (2017). Reversal of drug-resistance by noscapine chemo-sensitization in docet-axel resistant triple negative breast cancer. Sci Rep, 7(1): 15824.
20. Rowinsky EK, Eisenhauer EA, Chaudhry V, et al (1993). Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol, 20(4 Suppl 3): 1-15.
21. Ni J, Liu DY, Hu B, et al (2015). Relation-ship between icotinib hydrochloride ex-posure and clinical outcome in Chinese patients with advanced non–small cell lung cancer. Cancer, 121: 3146-3156.
22. Shi B, Zhang XB, Xu J, et al (2015). System-atic analysis of icotinib treatment for pa-tients with non-small cell lung cancer. Asian Pac J Cancer Prev, 16(13): 5521-5524.
23. Grunnet M, Sorensen JB (2012). Carci-noembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer, 76(2): 138-143.
24. Nakamura H, Nishimura T (2017). History, molecular features, and clinical im-portance of conventional serum bi-omarkers in lung cancer. Surg Today, 47(9): 1037-1059.
25. Chen X, Wang X, He H, et al (2015). Com-bination of circulating tumor cells with serum carcinoembryonic antigen enhanc-es clinical prediction of non-small cell lung cancer. PLoS One, 10(5): e0126276.
26. Zhuo M, Chen H, Zhang T, et al (2018). The potential predictive value of circulat-ing immune cell ratio and tumor marker in atezolizumab treated advanced non-small cell lung cancer patients. Cancer Bi-omark, 22(3): 467-476.
27. Lee S, Eo W, Jeon H, et al (2017). Prognos-tic Significance of Host-related Bi-omarkers for Survival in Patients with Advanced Non-Small Cell Lung Cancer. J Cancer, 8(15): 2974-2983.
28. Tan F, Shi Y, Wang Y, et al (2015). Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer. Future Oncol, 11(3): 385-397.
Published
2020-10-01
How to Cite
1.
LIN H, CHANG J, LI J. Effects of Docetaxel Combined with Icotinib on Serum Tumor Markers and Quality of Life of Patients with Advanced Non-Small Cell Lung Cancer. Iran J Public Health. 49(10):1885-1893.
Section
Original Article(s)